-
Promising New Weight Loss Drug?; Treating Shift-Work Disorder; Another Flu Vaccine Shortage?; FDA Actions
-
-
Two definite (culture-confirmed), and one probable, cases of K. kingae invasive disease were reported in Minnesota in October 2003, among children attending the same toddler classroom of a childcare center.
-
Musher and colleagues followed 207 patients with C. difficile colitis treated with appropriate (at least 1.5 gm/day) doses of metronidazole for at least 7 days. All patients had a positive stool ELISA assay for C. difficile toxin.
-
Saccharomyces boulardii (recently recognized as a strain of S. cerevisiae rather than a distinct species) is widely used as a probiotic for the treatment of diarrhea and for the prevention and treatment of C. difficile-associated colitis.
-
The FDA has recently approved daptomycin for use in skin and skin-structure infections, but this antibiotic failed the test of non-inferiority in a trial of severe community-acquired pneumonia.
-
The FDA has issued a public Health Advisory regarding the identification of 4 cases of toxic shock following medical abortion with Mifepristone (formerly RU-486) and intravaginal misoprostol in the United States.
-
Has your office telephone been ringing with questions from patients following a recent media report that the death rate for the transdermal contraceptive (Ortho Evra, Ortho-McNeil Pharmaceutical, Raritan, NJ) is three times that expected for oral contraceptives?
-
If emergency contraception (EC) is made available over the counter (OTC) in the United States, will it lead to more unprotected sex and increased use? Results from a just-published analysis of British use of the drug indicates that it will not.
-
How do you initiate mini-pills in a lactating woman who specifies such pill use for contraception?
